Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

33.62 +1.12 (+3.43%)
Streaming Delayed Price Updated: 1:44 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agios Pharmaceuticals

< Previous 1 2 3 Next >
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary  
Via Benzinga
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
The company is working on an oral treatment for alpha and beta thalassemia. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning! 
Via InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its  
Via Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
  
Via Benzinga
Why Shares of Schrödinger Rose This Week
Interest in the company's AI platform continues to drive the stock. 
Via The Motley Fool
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
  Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
  Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
  
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.